GSMA Launches Inclusive Tech Lab
The GSMA today announced the launch of the GSMA Inclusive Tech Lab, which will take a hands-on approach to research, testing and development of the inclusive technologies of the future. The Bill and Melinda Gates Foundation has provided three years of funding for the GSMA Inclusive Tech Lab, and will sit on the Advisory Group alongside industry representatives including GoPay, IDEMIA, KaiOS, Mowali, Telenor, the University of Washington, VEON and Vodafone.
“In launching the GSMA Inclusive Tech Lab, we are taking a bold new step to support and stimulate innovation through greater experimentation and a willingness to take risks,” said John Giusti, Chief Regulatory Officer, GSMA. “The GSMA Mobile for Development programme has already had a direct impact on improving the lives of 58 million people. The Lab will allow our team of dedicated ‘technopreneurs’ the opportunity to take a hands-on approach to break down the barriers to economic and social inclusion further.”
“We are proud to be collaborating with the GSMA and funding the Inclusive Tech Lab to strategize, build and pilot technologies to support the industry with innovations to drive financial inclusion for the poorest,” said Matt Bohan, Senior Programme Officer, Financial Services for the Poor at The Bill and Melinda Gates Foundation. “The Lab will enable us to create and explore products, from interoperability platforms to standardised APIs and more, that will help the industry to drive innovation to include poor people at a whole new pace and scale.”
The Lab will work on a range of areas that drive inclusion. These will comprise expanding the openness and interoperability of payment systems, service accessibility for women and vulnerable populations, and digital identities for unregistered people, as well as other topics of relevance. The GSMA, together with industry stakeholders, will establish and share proofs of concept aimed at increasing financial and digital inclusion for underserved groups.
The services of the Lab will be three-fold; research, innovation projects and technological assets (e.g. web-based test environments). The Lab will benefit from guidance received from leading industry figures making up its global Advisory Group, who will help to assess, prioritise, shape and contribute towards potential project ideas received by the Lab. Following direction from the Advisory Group, projects deemed feasible will be further researched and developed. The Lab will build readily usable products and insights up to proof-of-concept (and potentially support an initial commercial launch, as appropriate). Critically, the Lab will ensure learnings and Lab-developed solutions will be available to the broader industry, with the first results available to the industry in the first quarter of 2020.
Giusti concluded, “Today there are challenges of expanding access to financial services, bridging the digital services gap for women and vulnerable user groups, and providing digital identity solutions for the one billion individuals with no form of ID. These challenges drive our activity as we work on the transformative digital innovations of tomorrow.”
To find out more about the GSMA Inclusive Tech Lab, and how you can contribute, please go to the following link: www.gsma.com/lab
-ENDS-
About the GSMA
The GSMA represents the interests of mobile operators worldwide, uniting more than 750 operators and nearly 400 companies in the broader mobile ecosystem, including handset and device makers, software companies, equipment providers and internet companies, as well as organisations in adjacent industry sectors. The GSMA also produces the industry-leading MWC events held annually in Barcelona, Los Angeles and Shanghai, as well as the Mobile 360 Series of regional conferences.
For more information, please visit the GSMA corporate website at www.gsma.com. Follow the GSMA on Twitter: @GSMA.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190924005109/en/
Contact information
Media Contacts:
Gearóid Cashman
+44 79 7679 0169
GCashman@webershandwick.com
GSMA Press Office
pressoffice@gsma.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Post Malone and Crocs Launch Fourth Collaboration9.12.2019 20:57:00 EET | Press release
Crocs, Inc. (NASDAQ: CROX), a global leader in innovative, casual footwear for women, men and children, today announced their latest product collaboration with multi-platinum recording artist Post Malone. This ground-breaking fourth installment of the Post Malone x Crocs collaboration series features the Post Malone x Crocs Duet Max Clog, an innovative clog silhouette with a unique blue and black urban camo pattern, an exaggerated chunky outsole and pivotable backstraps with adjustable hook and loop closures. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191209005664/en/ The Post Malone x Crocs Duet Max Clog is an innovative clog silhouette with a unique blue and black urban camo pattern, an exaggerated chunky outsole and pivotable backstraps with adjustable hook and loop closures. This is the fourth collaboration between the duo. (Photo: Business Wire) The evolution of the Post Malone x Crocs partnership is evident over th
Knopp Biosciences Presents Data Further Characterizing Its Lead Kv7.2 Activator Drug Candidate for the Treatment of KCNQ2 Epileptic Encephalopathy at the American Epilepsy Society’s 2019 Annual Meeting9.12.2019 20:00:00 EET | Press release
Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for immunological and neurological diseases with high unmet need, today presented data characterizing KB-3061, the lead molecule in the Company’s Kv7 ion channel platform, at the American Epilepsy Society’s (AES) 2019 Annual Meeting in Baltimore, Maryland. Knopp is advancing the development of KB-3061 as a potential precision medicine treatment for the rare, neonatal disease KCNQ2 epileptic encephalopathy (KCNQ2-EE), a genetically defined disease associated with seizures beginning in the first days of life and profound neurodevelopmental delay. The disease is caused by dominant-negative mutations in the KCNQ2 gene, which produces a potassium channel, Kv7.2, critical to early brain development. Data presented at AES by Knopp scientists and its academic collaborators support the continued development of KB-3061 as a potential treatment for children with KCNQ2-EE. K
Murray Energy Corporation Posts Information to its Website Related to Murray Metallurgical9.12.2019 18:46:00 EET | Press release
Beginning on December 2, 2019, Murray Energy Corporation (the “Company”) engaged in confidential discussions under separate confidentiality agreements with certain members of an ad hoc group of superpriority lenders related Murray Metallurgical Coal Holdings, LLC and its subsidiaries (collectively, “Murray Metallurgical”). The confidentiality agreements require the Company to publicly disclose all material non-public information provided to such lenders on or prior to 8:30am (New York time) on December 9, 2019. The Company has posted certain previously undisclosed material to its website to satisfy its disclosure obligations under the confidentiality agreements. Such information can be viewed at the Investors portion of the Company’s website, located at murrayenergycorp.com/investors. Further inquiries should be directed to media@coalsource.com. Safe Harbor Statement The materials referenced in this release and posted to our website include forward-looking statements. A variety of fact
Seattle Genetics and Takeda Announce Additional Analyses of ADCETRIS® (Brentuximab Vedotin) ECHELON-1 and ECHELON-2 Phase 3 Clinical Trials at the 2019 ASH Annual Meeting9.12.2019 18:00:00 EET | Press release
Seattle Genetics, Inc. (Nasdaq:SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced additional analyses of results from the ECHELON-1 and ECHELON-2 frontline phase 3 trials of ADCETRIS® (brentuximab vedotin). These analyses were presented at the 61st Annual Meeting of the American Society of Hematology (ASH) taking place December 7-10, 2019 in Orlando, Fla. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, a defining marker of classical Hodgkin lymphoma and expressed on the surface of several types of peripheral T-cell lymphomas (PTCL). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191209005169/en/ The ECHELON-1 analysis highlighted a four-year update of the phase 3 clinical trial in a poster presentation. ECHELON-1 is evaluating ADCETRIS in combination with AVD (Adriamycin [doxorubicin], vinblastine and dacarbazine) compared to ABVD (Adriamycin [doxorubicin], bleomycin, vinblasti
Takeda Demonstrates Its Long-Standing Commitment to Advancing Treatments for Rare Bleeding Disorders with Studies Highlighting Real-World Evidence and Investigational Gene Therapy at ASH 20199.12.2019 18:00:00 EET | Press release
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) (“Takeda”), today presented nine hematology poster presentations at the 61st American Society of Hematology (ASH) Annual Meeting that underscore its commitment to advancing treatments for rare bleeding disorders by incorporating real-world data and developing innovative adeno-associated virus (AAV) gene therapies. Understanding Real-World Evidence to Advance Patient-Centric Innovation in Bleeding Disorders Real-world evidence from studies across many of Takeda’s portfolio of treatments for hemophilia demonstrate the cost savings and patient benefits resulting from ongoing personalized treatment. However, in von Willebrand disease, real-world evidence highlights the ongoing unmet clinical need for personalization, as it may enable improved treatment outcomes. Insights presented at ASH include: ADYNOVATE ® [Antihemophilic Factor (Recombinant), PEGylated]: In the poster “Real-World Age-Stratified FVIII Consumption and Bleed Outcom
Altasciences to Conduct Clinical Trial for Opioid Use Disorder Under NIH Funding9.12.2019 17:39:00 EET | Press release
Altasciences has been selected by Indivior PLC to conduct "A Phase I, Double-Blind, Placebo-Controlled, Randomized, Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of INDV-2000 (C4X_3256) Under Fasting and Fed Conditions in Healthy Volunteers", pursuant to the National Institutes of Health (NIH) Funding Opportunity Announcement RFA-DA-19-002, dedicated to the development of medications to prevent and treat opioid use disorder and overdose. The grant was made to Indivior by the NIH in fiscal year 2019, to apply scientific solutions to reverse the national opioid crisis. In March 2018, Indivior entered into a license agreement with C4X Discovery Holdings PLC (C4X) whereby Indivior obtained exclusive global rights to develop and commercialize INDV-2000 (C4X_3256). The first-in-human, single-ascending-dose study will be conducted in two parts — Part I: double-blind, placebo-controlled, randomized, single-ascending-dose study in fasted condition. Part II:
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom